ADC Therapeutics (ADCT) Other Non Operating Income (2020 - 2026)

ADC Therapeutics (ADCT) has reported Other Non Operating Income for 7 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non Operating Income rose 1196.55% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 37.64% YoY) and the FY2025 annual result came in at -$33000.0, down 103.16% from the prior year.
• Other Non Operating Income improved to $2.6 million in Q1 2026 per ADCT's latest filing, from -$979000.0 in the prior quarter.
• Over the last five years, Other Non Operating Income for ADCT reached as high as $22.5 million in Q1 2022 and fell as low as -$48.2 million in Q3 2022.
• A 5-year average of $551294.1 and a median of $860000.0 in 2023 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2024 — Other Non Operating Income slumped 6753.85% — and 2026, when it jumped 1196.55%.
• Year by year, Other Non Operating Income stood at $17.5 million in 2022, then slumped by 70.07% to $5.2 million in 2023, then slumped by 114.14% to -$739000.0 in 2024, then slumped by 32.48% to -$979000.0 in 2025, then soared by 368.85% to $2.6 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $2.6 million, -$979000.0, and $925000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.